Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer

BACKGROUND: Nelfinavir (NFV), an HIV‐1 protease inhibitor, has been shown to sensitize cancer cells to chemoradiation (CRT). The objectives of this phase 1 trial were to evaluate safety and identify the recommended phase 2 dose of NFV added to concurrent CRT for locally advanced cervical cancer. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia‐Soto, Arlene E., McKenzie, Nathalie D., Whicker, Margaret E., Pearson, Joseph M., Jimenez, Edward A., Portelance, Lorraine, Hu, Jennifer J., Lucci, Joseph A., Qureshi, Rehman, Kossenkov, Andrew, Schwartz, Lauren, Mills, Gordon B., Maity, Amit, Lin, Lilie L., Simpkins, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252376/
https://www.ncbi.nlm.nih.gov/pubmed/33932031
http://dx.doi.org/10.1002/cncr.33449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252376/
https://www.ncbi.nlm.nih.gov/pubmed/33932031
http://dx.doi.org/10.1002/cncr.33449

Ejemplares similares